Intervention
disitamab vedotin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialNCT06278870 · 2023-09-06
RECRUITINGA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · 2024-05-20
ACTIVE_NOT_RECRUITINGA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231 · 2023-11-14
ACTIVE_NOT_RECRUITINGCommon conditions
Advanced Breast Cancer1Advanced Gastric Cancer1Breast Neoplasms1Carcinoma, Non-Small-Cell Lung1Endometrial Neoplasms1First-line Treatment1Gastroesophageal Junction Adenocarcinoma1Head and Neck Neoplasms1HER2 Low Breast Neoplasms1HER2 Positive Breast Neoplasms1HER2-positive Metastatic Breast Cancer1Metastatic Breast Cancer1Metastatic Gastric Cancer1Ovarian Neoplasms1Stomach Neoplasms1Triple Negative Breast Neoplasms1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING2
RECRUITING1
Phase mix
PHASE22
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.